Abstract
Following induction therapy and 4g/m2 cyclophosphamide, a single dose of 12mg polyethyleneglycol-conjugated G-CSF (pegfilgrastim; n = 12) or daily doses of unconjugated G-CSF (8.5 μg/kg/day) (n = 12) were administered to myeloma patients. Pegfilgrastim was associated with an earlier leukocyte recovery (12 vs 14 days) and peripheral blood CD34 + cell peak (12 vs 15 days). The peripheral blood CD34 + cell peak was lower in the pegfilgrastim group (78 vs 111/μl). Following high-dose melphalan (200mg/m2) and autografting, leukocyte and platelet reconstitution was similar in both groups and stable blood counts were observed 100 days post transplant. In summary, a single dose of pegfilgrastim after chemotherapy is capable of mobilizing a sufficient number of CD34 + cells for successful autografting with early engraftment and sustained hematological reconstitution in patients with myeloma. These data provide the basis for randomized studies evaluating the optimal dose and time of pegfilgrastim as well as long-term outcome in larger cohorts of patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 33-36 |
| Number of pages | 4 |
| Journal | Bone Marrow Transplantation |
| Volume | 35 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2005 |
| Externally published | Yes |
Fingerprint
Keywords
- G-CSF
- Multiple myeloma
- Polyethylenglycole
- Stem cell mobilization
- Stem cell transplantation
ASJC Scopus subject areas
- Hematology
- Transplantation
Cite this
Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. / Steidl, Ulrich G.; Fenk, R.; Bruns, I.; Neumann, F.; Kondakci, M.; Hoyer, B.; Gräf, T.; Rohr, U. P.; Bork, S.; Kronenwett, R.; Haas, R.; Kobbe, G.
In: Bone Marrow Transplantation, Vol. 35, No. 1, 01.2005, p. 33-36.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma
AU - Steidl, Ulrich G.
AU - Fenk, R.
AU - Bruns, I.
AU - Neumann, F.
AU - Kondakci, M.
AU - Hoyer, B.
AU - Gräf, T.
AU - Rohr, U. P.
AU - Bork, S.
AU - Kronenwett, R.
AU - Haas, R.
AU - Kobbe, G.
PY - 2005/1
Y1 - 2005/1
N2 - Following induction therapy and 4g/m2 cyclophosphamide, a single dose of 12mg polyethyleneglycol-conjugated G-CSF (pegfilgrastim; n = 12) or daily doses of unconjugated G-CSF (8.5 μg/kg/day) (n = 12) were administered to myeloma patients. Pegfilgrastim was associated with an earlier leukocyte recovery (12 vs 14 days) and peripheral blood CD34 + cell peak (12 vs 15 days). The peripheral blood CD34 + cell peak was lower in the pegfilgrastim group (78 vs 111/μl). Following high-dose melphalan (200mg/m2) and autografting, leukocyte and platelet reconstitution was similar in both groups and stable blood counts were observed 100 days post transplant. In summary, a single dose of pegfilgrastim after chemotherapy is capable of mobilizing a sufficient number of CD34 + cells for successful autografting with early engraftment and sustained hematological reconstitution in patients with myeloma. These data provide the basis for randomized studies evaluating the optimal dose and time of pegfilgrastim as well as long-term outcome in larger cohorts of patients.
AB - Following induction therapy and 4g/m2 cyclophosphamide, a single dose of 12mg polyethyleneglycol-conjugated G-CSF (pegfilgrastim; n = 12) or daily doses of unconjugated G-CSF (8.5 μg/kg/day) (n = 12) were administered to myeloma patients. Pegfilgrastim was associated with an earlier leukocyte recovery (12 vs 14 days) and peripheral blood CD34 + cell peak (12 vs 15 days). The peripheral blood CD34 + cell peak was lower in the pegfilgrastim group (78 vs 111/μl). Following high-dose melphalan (200mg/m2) and autografting, leukocyte and platelet reconstitution was similar in both groups and stable blood counts were observed 100 days post transplant. In summary, a single dose of pegfilgrastim after chemotherapy is capable of mobilizing a sufficient number of CD34 + cells for successful autografting with early engraftment and sustained hematological reconstitution in patients with myeloma. These data provide the basis for randomized studies evaluating the optimal dose and time of pegfilgrastim as well as long-term outcome in larger cohorts of patients.
KW - G-CSF
KW - Multiple myeloma
KW - Polyethylenglycole
KW - Stem cell mobilization
KW - Stem cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=19944429579&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=19944429579&partnerID=8YFLogxK
U2 - 10.1038/sj.bmt.1704702
DO - 10.1038/sj.bmt.1704702
M3 - Article
C2 - 15531906
AN - SCOPUS:19944429579
VL - 35
SP - 33
EP - 36
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 1
ER -